• 1.

    Yu A, et al. Brenner and Rector's The Kidney. 2-Volume Set, 11th edition (Elsevier); 2019.

  • 2.

    Sutton RA, Domrongkitchaiporn S. Abnormal renal magnesium handling. Miner Electrolyte Metab 1993; 19:232240. PMID: 8264509

  • 3.

    Elisaf M, et al. Hypomagnesemic hypokalemia and hypocalcemia: Clinical and laboratory characteristics. Miner Electrolyte Metab 1997; 23:105112. PMID: 9252977

  • 4.

    Manohar S, Leung N. Cisplatin nephrotoxicity: A review of the literature. J Nephrol 2018; 31:1525. doi: 10.1007/s40620-017-0392-z

  • 5.

    Pabla N, et al. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol 2009; 296:F505F511. doi: 10.1152/ajprenal.90545.2008

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Houillier P. Mechanisms and regulation of renal magnesium transport. Annu Rev Physiol 2014; 76:411430. doi: 10.1146/annurev-physiol-021113-170336

  • 7.

    Zeidel ML, et al. A new CJASN series: Renal physiology for the clinician. Clin J Am Soc Nephrol 2014; 9:1271. doi: 10.2215/CJN.10191012

  • 8.

    de Baaij JHF, et al. Regulation of magnesium balance: Lessons learned from human genetic disease. Clin Kidney J 2012; 5 (Suppl 1):i15-i24. doi: 10.1093/ndtplus/sfr164

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Perazella MA. Onco-nephrology: Renal toxicities of chemotherapeutic agents. Clin J Am Soc Nephrol 2012; 7:17131721. doi: 10.2215/CJN.02780312

  • 10.

    Workeneh BT, et al. Hypomagnesemia in the cancer patient. Kidney360 2021; 2:154166. doi: https://doi.org/10.34067/KID.0005622020

  • 11.

    Lajer H, Daugaard G. Cisplatin and hypomagnesemia. Cancer Treat Rev 1999; 25:4758. doi: 10.1053/ctrv.1999.0097

  • 12.

    Huang C, Kuo E. Mechanism of hypokalemia in magnesium deficiency. J Am Soc Nephrol 2007; 18:26492652. doi: 10.1681/ASN.2007070792

  • 13.

    Crona DJ, et al. A systematic review of strategies to prevent cisplatin-induced nephrotoxicity. Oncologist 2017; 22:609619. doi: 10.1634/theoncologist.2016-0319

Magnesium, the Forgotten Cation A Skeleton Key Group FOAMed Feature

Dominique Tomacruz Dominique Tomacruz, MD, is SKG Executive Editor and a Clinical Fellow at Philippine General Hospital, Manila. Sayna Norouzi, MD, is SKG Editor-in-Chief and Assistant Professor of Medicine, Department of Nephrology, Loma Linda University Medical Center, Loma Linda, CA. Joel M. Topf, MD, FACP, is an SKG Faculty Mentor and Assistant Clinical Professor of Medicine, Oakland University William Beaumont School of Medicine, Rochester, MI.

Search for other papers by Dominique Tomacruz in
Current site
Google Scholar
PubMed
Close
,
Sayna Norouzi Dominique Tomacruz, MD, is SKG Executive Editor and a Clinical Fellow at Philippine General Hospital, Manila. Sayna Norouzi, MD, is SKG Editor-in-Chief and Assistant Professor of Medicine, Department of Nephrology, Loma Linda University Medical Center, Loma Linda, CA. Joel M. Topf, MD, FACP, is an SKG Faculty Mentor and Assistant Clinical Professor of Medicine, Oakland University William Beaumont School of Medicine, Rochester, MI.

Search for other papers by Sayna Norouzi in
Current site
Google Scholar
PubMed
Close
, and
Joel M. Topf Dominique Tomacruz, MD, is SKG Executive Editor and a Clinical Fellow at Philippine General Hospital, Manila. Sayna Norouzi, MD, is SKG Editor-in-Chief and Assistant Professor of Medicine, Department of Nephrology, Loma Linda University Medical Center, Loma Linda, CA. Joel M. Topf, MD, FACP, is an SKG Faculty Mentor and Assistant Clinical Professor of Medicine, Oakland University William Beaumont School of Medicine, Rochester, MI.

Search for other papers by Joel M. Topf in
Current site
Google Scholar
PubMed
Close
Restricted access
Save